← All themes

GLP-1 & Obesity

GLP-1 medicines treat obesity and diabetes, and have grown into one of the largest drug categories ever launched. Their reach extends past medicine, because a change in how much people eat moves whole consumer industries.

92 stocks

Obesity Second-Order Effects

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Pfizer PFE $168B	3,088	-72	-2%	$170B
2	2 Eli Lilly LLY $1.12T	2,485	+39	+2%	$257B
3	3 Amgen AMGN $235B	2,324	-29	-1%	$92.5B
4	4 Becton Dickinson BDX $52.8B	1,506	-29	-2%	$55.8B
5	5 McKesson MCK $116B	1,194	+29	+2%	$42B
6	6 Regeneron Pharmaceuticals REGN $82B	1,080	+16	+2%	$64B
7	7 AstraZeneca AZN $259B	966	-50	-5%	$28.3B
8	8 Novo Nordisk NVO $173B	907	-25	-3%	$13.8B
9	9 Conagra Brands CAG $6.77B	803	+12	+2%	$12.9B
10	10 ResMed RMD $34.1B	668	-9	-1%	$21B
11	11 West Pharmaceutical WST $27B	637	-18	-3%	$16.9B
12	12 Lamb Weston LW $7.47B	595	+38	+7%	$10B
13	13 DELISTED CATALENT, INC. CTLT	506	-38	-7%	$13.2B
14	14 Embecta EMBC $365M	461	-22	-5%	$1.57B
15	15 DaVita DVA $12.1B	441	-21	-5%	$6.61B
16	16 Teva Pharmaceutical Industries Limited TEVA $47.9B	430	-26	-6%	$4.51B
17	17 Inspire Medical Systems INSP $2.03B	301	+14	+5%	$5.01B
18	18 BellRing Brands BRBR $1.05B	275	-1	-0.4%	$2.6B
19	19 Medifast MED $135M	263	-21	-7%	$1.03B
20	TWNK 20 DELISTED Hostess Brands, Inc. Class A Common Stock TWNK	256	+3	+1%	$3.31B
21	21 Accendra Health ACH $20.1M	225	-24	-10%	$1.85B
22	22 Opko Health OPK $1.2B	221	-10	-4%	$350M
23	23 Amphastar Pharmaceuticals AMPH $1.12B	205	-18	-8%	$839M
24	24 Herbalife HLF $1.53B	201	-3	-1%	$1.94B
25	25 DELISTED WW International WW	193	+1	+0.5%	$227M